Connexin 43 antibody and its use

JP2026090576APending Publication Date: 2026-06-02ALAMAB THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
ALAMAB THERAPEUTICS INC
Filing Date
2026-03-03
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

Current treatments for cancer metastasis, such as bisphosphonate drugs, are effective but associated with serious side effects, and there is a need for alternative methods to manage Cx43 hemichannels in osteocytes to treat conditions like cancer metastasis, osteosarcoma, osteoporosis, or osteopenia.

Method used

Development of anti-Cx43 antibodies or antigen-binding fragments that promote the opening of Cx43 hemichannels in osteocytes, which can be used in pharmaceutical compositions to treat conditions like cancer metastasis, osteosarcoma, osteoporosis, or osteopenia.

Benefits of technology

The anti-Cx43 antibodies effectively promote the opening of Cx43 hemichannels, offering a potential treatment for cancer metastasis and other bone-related conditions with reduced toxicity and improved stability compared to existing bisphosphonate drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026090576000012
    Figure 2026090576000012
  • Figure 2026090576000013
    Figure 2026090576000013
  • Figure 2026090576000014
    Figure 2026090576000014
Patent Text Reader

Abstract

To provide compositions and methods for treating diseases or conditions associated with insufficient opening of Cx43 hemichannels in osteocytes, preferably for treating cancer, cancer metastasis, osteosarcoma, osteoporosis, or osteopenia. [Solution] In one embodiment, an anti-Cx43 antibody or an antigen-binding fragment thereof is provided herein, comprising: first, second, and third heavy chain complementarity-determining region (CDR) sequences having the amino acid sequences of SEQ ID NOs. 1, 2, and 3, respectively; and first, second, and third light chain CDR sequences having the amino acid sequences of SEQ ID NOs. 4, 5, and 6, respectively.
Need to check novelty before this filing date? Find Prior Art